MX377093B - Formulaciones de apolipoproteína de dosificación fija. - Google Patents
Formulaciones de apolipoproteína de dosificación fija.Info
- Publication number
- MX377093B MX377093B MX2014006589A MX2014006589A MX377093B MX 377093 B MX377093 B MX 377093B MX 2014006589 A MX2014006589 A MX 2014006589A MX 2014006589 A MX2014006589 A MX 2014006589A MX 377093 B MX377093 B MX 377093B
- Authority
- MX
- Mexico
- Prior art keywords
- fixed dosage
- formulation
- apolipoprotein formulation
- apolipoprotein
- dosage apolipoprotein
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000007592 Apolipoproteins Human genes 0.000 title abstract 4
- 108010071619 Apolipoproteins Proteins 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 abstract 4
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 abstract 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract 1
- 229940099352 cholate Drugs 0.000 abstract 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000007056 liver toxicity Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- -1 phosphatidylcholine Chemical class 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011905368A AU2011905368A0 (en) | 2011-12-21 | Dosing regime for apolipoprotein formulations | |
| PCT/AU2012/001345 WO2013090978A1 (en) | 2011-12-21 | 2012-11-02 | Dosage regime for apolipoprotein formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014006589A MX2014006589A (es) | 2014-10-17 |
| MX377093B true MX377093B (es) | 2025-03-07 |
Family
ID=48667485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006589A MX377093B (es) | 2011-12-21 | 2012-11-02 | Formulaciones de apolipoproteína de dosificación fija. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20140378376A1 (enExample) |
| EP (1) | EP2793913B1 (enExample) |
| JP (2) | JP6144276B2 (enExample) |
| KR (3) | KR20190084334A (enExample) |
| CN (2) | CN104010646A (enExample) |
| AU (1) | AU2012310259C1 (enExample) |
| BR (1) | BR112014014403A8 (enExample) |
| CA (1) | CA2857968A1 (enExample) |
| DK (1) | DK2793913T3 (enExample) |
| ES (1) | ES2955110T3 (enExample) |
| IL (1) | IL233236A0 (enExample) |
| MX (1) | MX377093B (enExample) |
| PL (1) | PL2793913T3 (enExample) |
| RU (1) | RU2014129505A (enExample) |
| SG (1) | SG11201402556RA (enExample) |
| WO (1) | WO2013090978A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9645037B2 (en) | 2011-09-28 | 2017-05-09 | Hunter Engineering Company | Method and apparatus for wheel assembly lateral force measurement |
| KR20190084334A (ko) * | 2011-12-21 | 2019-07-16 | 시에스엘 리미티드 | 아포지질단백질 제형을 위한 용량 용법 |
| IL266428B2 (en) | 2016-11-10 | 2024-12-01 | Csl Ltd | High-density lipoprotein (HDL) is restored to treat myocardial infarction |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61152632A (ja) * | 1984-12-26 | 1986-07-11 | Dai Ichi Seiyaku Co Ltd | 抗動脈硬化剤 |
| US5652339A (en) | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| JP4344136B2 (ja) * | 2000-11-10 | 2009-10-14 | エフ・ホフマン−ラ・ロシュ・リミテッド | アポリポタンパク質類似体 |
| MXPA04002848A (es) * | 2001-09-28 | 2005-06-06 | Esperion Therapeutics Inc | Prevencion y tratamiento de restenosis por administracion local de medicamento. |
| US20040067873A1 (en) * | 2002-05-17 | 2004-04-08 | Dasseux Jean-Louis H. | Method of treating dyslipidemic disorders |
| JP2006508045A (ja) * | 2002-07-30 | 2006-03-09 | エスペリオン セラピューティクス，インコーポレイテッド | ヒト以外の動物のアポリポプロテインａ−ｉタンパク質の使用方法 |
| CN1870894B (zh) * | 2003-10-20 | 2011-08-10 | 埃斯普里昂治疗公司 | 用于治疗和预防急性冠状动脉综合征的药物制剂、方法和给药方案 |
| PE20050438A1 (es) * | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| JP2009505652A (ja) * | 2005-08-26 | 2009-02-12 | セレニス セラピューティクス ホールディング エスア | 乳酸菌においてアポリポタンパク質遺伝子生成物を生成するための組成物および方法 |
| US20090297577A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Local Delivery of Apolipoproteins and Their Derivatives |
| KR20190084334A (ko) * | 2011-12-21 | 2019-07-16 | 시에스엘 리미티드 | 아포지질단백질 제형을 위한 용량 용법 |
-
2012
- 2012-11-02 KR KR1020197019295A patent/KR20190084334A/ko not_active Ceased
- 2012-11-02 CN CN201280063210.4A patent/CN104010646A/zh active Pending
- 2012-11-02 MX MX2014006589A patent/MX377093B/es active IP Right Grant
- 2012-11-02 KR KR1020147020291A patent/KR20140107536A/ko not_active Ceased
- 2012-11-02 DK DK12859136.9T patent/DK2793913T3/da active
- 2012-11-02 AU AU2012310259A patent/AU2012310259C1/en active Active
- 2012-11-02 PL PL12859136.9T patent/PL2793913T3/pl unknown
- 2012-11-02 EP EP12859136.9A patent/EP2793913B1/en active Active
- 2012-11-02 CA CA2857968A patent/CA2857968A1/en not_active Abandoned
- 2012-11-02 US US14/364,764 patent/US20140378376A1/en not_active Abandoned
- 2012-11-02 WO PCT/AU2012/001345 patent/WO2013090978A1/en not_active Ceased
- 2012-11-02 KR KR1020207009276A patent/KR102766038B1/ko active Active
- 2012-11-02 SG SG11201402556RA patent/SG11201402556RA/en unknown
- 2012-11-02 BR BR112014014403A patent/BR112014014403A8/pt not_active Application Discontinuation
- 2012-11-02 RU RU2014129505A patent/RU2014129505A/ru unknown
- 2012-11-02 CN CN202110675512.8A patent/CN113398245A/zh active Pending
- 2012-11-02 JP JP2014547627A patent/JP6144276B2/ja active Active
- 2012-11-02 ES ES12859136T patent/ES2955110T3/es active Active
-
2014
- 2014-06-18 IL IL233236A patent/IL233236A0/en active IP Right Grant
-
2016
- 2016-02-26 US US15/054,358 patent/US20160175392A1/en not_active Abandoned
-
2017
- 2017-03-10 JP JP2017045676A patent/JP2017128586A/ja active Pending
-
2023
- 2023-08-14 US US18/449,039 patent/US20240216467A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123945T1 (el) | Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες | |
| MX2012014928A (es) | Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. | |
| CY1126136T1 (el) | Μεθοδοι θεραπειας της αρθριτιδας | |
| CY1124499T1 (el) | Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα | |
| NZ743714A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| CR9089A (es) | Compuestos y derivados de dibencil amina | |
| BR112015022868A2 (pt) | composições de mrna de cftr e usos e métodos relacionados | |
| CR20180086A (es) | Tricíclicos sustituidos y métodos para usarlos | |
| PA8598901A1 (es) | Compuesto de quinolina y quinoxalina | |
| MX383117B (es) | Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma. | |
| PE20150203A1 (es) | Formulas de testosterona proliposomal | |
| MX352328B (es) | Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. | |
| MX2015012201A (es) | Formulaciones modificadas de liposomas de docetaxel. | |
| EA201490544A1 (ru) | Препараты и лекарственные формы на основе окисленных фосфолипидов | |
| EA201690284A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
| WO2014089511A3 (en) | Administering compositions comprising docosapentaenoic acid | |
| MX2018004637A (es) | Ácidos nucleicos p-etoxi para formulacion liposomal. | |
| NZ631131A (en) | Reconstituted hdl formulation | |
| ECSP12011862A (es) | Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen | |
| CR9012A (es) | Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina | |
| BR112014014403A8 (pt) | "formulação de apolipoproteína, seus método de produção e uso no tratamento profilático ou terapêutico de doenças cardiovasculares, hipercolesterolemia ou hipocolesterolemia, bem como kit | |
| NO20083641L (no) | Dibenzylaminforbindelser, samt derivater derav | |
| WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same | |
| CO6660080A1 (es) | Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen | |
| MX2012007682A (es) | Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |